Literature DB >> 17012310

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Yutaka Kanda1, Tsuyoshi Yamada, Katsuhiro Mori, Akira Okazaki, Miho Inoue, Kazuko Kitajima-Miyama, Reiko Kuni-Kamochi, Ryosuke Nakano, Keiichi Yano, Shingo Kakita, Kenya Shitara, Mitsuo Satoh.   

Abstract

The structure of asparagine-linked oligosaccharides attached to the antibody constant region (Fc) of human immunoglobulin G1 (IgG1) has been shown to affect the pharmacokinetics and antibody effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, it is still unclear how differences in the N-linked oligosaccharide structures impact the biological activities of antibodies, especially those lacking core fucose. Here, we succeeded in generating core fucose-lacking human IgG1 antibodies with three different N-linked Fc oligosaccharides, namely, a high-mannose, hybrid, and complex type, using the same producing clone, and compared their activities. Cultivation of an alpha-1,6-fucosyltransferase (FUT8) knockout Chinese hamster ovary cell line in the presence or absence of a glycosidase inhibitor (either swainsonine or kifunensine) yielded antibody production of each of the three types without contamination by the others. Two of three types of nonnaturally occurring atypical oligosaccharide IgG1, except the complex type, reduced the affinity for both human lymphocyte receptor IIIa (FcgammaRIIIa) and the C1q component of the complement, resulting in reduction of ADCC and CDC. The bulky structure of the nonreducing end of N-linked Fc oligosaccharides is considered to contribute the CDC change, whereas the structural change in the reducing end, i.e. the removal of core fucose, causes ADCC enhancement through improved FcgammaRIIIa binding. In the pharmacokinetic profile, although no significant difference of human neonatal Fc receptor (FcRn)-binding affinity was observed among the three types, the complex type showed longer serum half-lives than the other types irrespective of core fucosylation in mice, which also suggests the contribution of the nonreducing end structure. The present study provides basic information on the effects of core fucose-lacking N-linked Fc oligosaccharides on antibody biological activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012310     DOI: 10.1093/glycob/cwl057

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  112 in total

1.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay.

Authors:  Bhavin S Parekh; Elaine Berger; Sharon Sibley; Suntara Cahya; Liqun Xiao; Melinda Ann LaCerte; Peter Vaillancourt; Scott Wooden; Dennis Gately
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 4.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 5.  Biosimilarity Versus Manufacturing Change: Two Distinct Concepts.

Authors:  Paul Declerck; Mourad Farouk-Rezk; Pauline M Rudd
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

6.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

Review 7.  Structure and function of immunoglobulins.

Authors:  Harry W Schroeder; Lisa Cavacini
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

8.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.

Authors:  Guozhang Zou; Hirofumi Ochiai; Wei Huang; Qiang Yang; Cishan Li; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2011-11-01       Impact factor: 15.419

9.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering.

Authors:  Martin Frank; Ross C Walker; William N Lanzilotta; James H Prestegard; Adam W Barb
Journal:  J Mol Biol       Date:  2014-02-09       Impact factor: 5.469

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.